Icecure Medical Ltd Ord (ICCM) Stock Price, Quote & News

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 623 0333

Fax: 972 4 623 0222

Website: www.icecure-medical.com

Address:

7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel

SuperBusa Feb. 3 at 6:58 PM

$ICCM

0 · Reply

noonknight Feb. 2 at 12:59 AM

$ICCM Based on the most recent financial data as of early 2026, IceCure Medical (ICCM) is estimated to have approximately 6 to 8 months of cash runway remaining before it will likely need additional financing.Financial Snapshot (Preliminary FY 2025)According to the CEO's January 2026 shareholder letter and the Q3 2025 earnings report:Cash on Hand: Approximately $8.9 million (as of December 31, 2025).Net Loss: The company reported a net loss of approximately $10.8 million for the first nine months of 2025 (roughly $3.6 million per quarter).Recent Funding: ICCM successfully raised capital in late 2025 via a $10 million rights offering and an "at-the-market" (ATM) facility, which bolstered the cash position following the FDA marketing authorization for breast cancer treatment in October 2025.Runway AnalysisGiven the current burn rate and strategic objectives, here is how the runway looks:MetricEstimateEstimated Quarterly Burn~$3.5M – $3.8MCURRENT Cash (Dec 31, 2025)$8.9M

1 · Reply

GJ_Rockabilt Jan. 30 at 2:23 PM

$ICCM This Stock drives me crazy. I've been in and out. I'm Out, now. Today is last day to sign up for FREE Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

Lyn30 Jan. 29 at 6:29 PM

$ICCM Only stock I regret putting money as well as disappointed. One account avg 1.01, three account .64. Point is here just concerned if they drag it to .30. The way most Israeli stocks do. Then do RS. I thought its different as huge potential. But they ducked me. If they do have to lose most investment here . I can easily avg down cause I have big portfolio but won’t cause it’s about calculation .

1 · Reply

prismmarketview Jan. 28 at 9:11 PM

$ICCM IceCure Medical received FDA De Novo marketing authorization for its ProSense System to treat patients with early-stage, low-risk breast cancer. This milestone allows for a cryoablation alternative to surgery for certain breast cancer patients in the U.S. https://prismmarketview.com/companies/icecure-medical-ltd/

0 · Reply

SuperBusa Jan. 28 at 2:47 PM

$ICCM

0 · Reply

Joe_088 Jan. 28 at 1:48 PM

$ICCM IceCure's U.S. commercial team continues to see accelerating interest in ProSense®. During recent months, systems were sold and installed at new locations across North America, including at one of the most highly regarded medical institutions in the U.S., reflecting growing clinical interest following the FDA's marketing authorization

0 · Reply

Planetpaprika Jan. 28 at 1:36 PM

$ICCM https://ir.icecure-medical.com/news-events/press-releases/detail/204/icecure-celebrates-american-society-of-breast-surgeons-asbrs-proposed-breast-cancer-treatment-guidelines-which-include-cryoablation-for-low-risk-breast-cancer

0 · Reply

Lyn30 Jan. 28 at 4:18 AM

$ICCM I never sell any of my stock until it reach target . This one I should have sold . Minimum 4 times I had decent profit . But I didn’t sell. This is my last israeliii stock , after that I will only shart.its very hard to make money from Israeliii stocks, that’s why normally I don’t touch. This one accidentally touched due to potential. Then I rewind the button , all israeliii stock looks like same , they have huge potential but stock do same way imo. Once in a while they run big , if anyone catch that then can make huge. Otherwise sitting there seeing small bump here and there imo .

0 · Reply

patcoin Jan. 26 at 8:22 PM

$ICCM high risk high reward. great summary: https://everyticker.com/quote/ICCM/analysis/regulatory-monopoly-meets-commercial-execution-challenge-at-icecure-medical-nasdaq-iccm taking a small position now looking to average down over the coming months if needed. GLHF

0 · Reply

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

Jan 12, 2026, 8:30 AM EST - 22 days ago

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

Dec 17, 2025, 8:30 AM EST - 6 weeks ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 10, 2025, 8:30 AM EST - 7 weeks ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Dec 5, 2025, 8:30 AM EST - 2 months ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Nov 19, 2025, 12:53 PM EST - 2 months ago

IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript

Nov 19, 2025, 8:54 AM EST - 2 months ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 18, 2025, 8:30 AM EST - 2 months ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 14, 2025, 4:30 PM EST - 2 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 12, 2025, 8:30 AM EST - 2 months ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 10, 2025, 8:30 AM EST - 3 months ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 3, 2025, 8:30 AM EST - 3 months ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Oct 13, 2025, 8:30 AM EDT - 4 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 9, 2025, 8:30 AM EDT - 4 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 6, 2025, 11:25 AM EDT - 4 months ago

IceCure Medical Ltd - Special Call

Oct 3, 2025, 12:28 PM EDT - 4 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:19 PM EDT - 4 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Sep 30, 2025, 8:30 AM EDT - 4 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 4 months ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 18, 2025, 8:30 AM EDT - 4 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 15, 2025, 8:30 AM EDT - 5 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 8, 2025, 8:30 AM EDT - 5 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 4, 2025, 8:30 AM EDT - 5 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Aug 13, 2025, 1:08 PM EDT - 6 months ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 8:30 AM EDT - 6 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 6, 2025, 8:30 AM EDT - 6 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Jul 29, 2025, 9:00 AM EDT - 6 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 25, 2025, 9:00 AM EDT - 6 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 24, 2025, 9:00 AM EDT - 6 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 10, 2025, 8:00 AM EDT - 7 months ago

IceCure Announces Commencement of Rights Offering

Jul 3, 2025, 8:30 AM EDT - 7 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jun 25, 2025, 9:23 AM EDT - 7 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 9, 2025, 8:30 AM EDT - 8 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

May 28, 2025, 4:26 PM EDT - 8 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 8:30 AM EDT - 8 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

May 21, 2025, 8:30 AM EDT - 9 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 6, 2025, 8:30 AM EDT - 9 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

Apr 30, 2025, 8:30 AM EDT - 9 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 10 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 22, 2025, 8:30 AM EDT - 10 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Mar 27, 2025, 1:45 PM EDT - 11 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:30 AM EDT - 11 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 24, 2025, 8:30 AM EDT - 11 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 21, 2025, 8:30 AM EDT - 11 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 20, 2025, 8:30 AM EDT - 11 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 18, 2025, 8:30 AM EDT - 11 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 17, 2025, 8:30 AM EDT - 11 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Mar 10, 2025, 8:30 AM EDT - 11 months ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

Feb 24, 2025, 8:30 AM EST - 1 year ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Feb 4, 2025, 8:30 AM EST - 1 year ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

SuperBusa Feb. 3 at 6:58 PM

$ICCM

0 · Reply

noonknight Feb. 2 at 12:59 AM

1 · Reply

GJ_Rockabilt Jan. 30 at 2:23 PM

0 · Reply

Lyn30 Jan. 29 at 6:29 PM

1 · Reply

prismmarketview Jan. 28 at 9:11 PM

0 · Reply

SuperBusa Jan. 28 at 2:47 PM

$ICCM

0 · Reply

Joe_088 Jan. 28 at 1:48 PM

0 · Reply

Planetpaprika Jan. 28 at 1:36 PM

0 · Reply

Lyn30 Jan. 28 at 4:18 AM

0 · Reply

patcoin Jan. 26 at 8:22 PM

0 · Reply

bigcucus35 Jan. 24 at 12:50 AM

$ICCM 6% after hours? weird

1 · Reply

Joe_088 Jan. 22 at 1:31 PM

$ICCM

0 · Reply

noonknight Jan. 21 at 1:38 AM

$ICCM https://everyticker.com/quote/ICCM/analysis/regulatory-monopoly-meets-commercial-execution-challenge-at-icecure-medical-nasdaq-iccm IceCure's market positioning reflects the classic medtech startup dilemma: clinically validated technology that has yet to achieve commercial scale. The company sells capital equipment (cryoablation consoles) and high-margin disposable probes that provide recurring revenue. Its geographic footprint spans North America, Europe, Japan, and Latin America, yet total revenue reached only $3.29 million in 2024. This disparity between technological capability and commercial execution defines the investment risk. While the company has secured regulatory approvals in Switzerland, Israel, and Brazil, its sales organization remains nascent, with just 20 commercial sites in the U.S. prior to FDA authorization.

0 · Reply

noonknight Jan. 21 at 1:33 AM

$ICCM https://everyticker.com/quote/ICCM/analysis/regulatory-monopoly-meets-commercial-execution-challenge-at-icecure-medical-nasdaq-iccm The agency's October 2025 decision came with stringent conditions: any competitor seeking 510(k) clearance for a different cryoablation system must submit five years of follow-up data, use a liquid nitrogen-based system, and employ specific probe engagement. To IceCure's knowledge, no other company is currently conducting such a study in the U.S. This creates a regulatory moat that protects the company's first-mover advantage while establishing a high barrier that even large competitors like Boston Scientific (BSX) and Medtronic (MDT) cannot quickly overcome.

0 · Reply

NVDAMillionaire Jan. 20 at 9:05 PM

$ICCM Excellent article that nails exactly where ICCM stands right now. So if you want to update your ICCM knowledge or get acquainted with ICCM, this is a must read. https://everyticker.com/quote/ICCM/analysis/regulatory-monopoly-meets-commercial-execution-challenge-at-icecure-medical-nasdaq-iccm

0 · Reply

Leemarvin70 Jan. 20 at 8:42 PM

$ICCM $VERO la paciencia se te acaba con el RS

1 · Reply

SuperBusa Jan. 20 at 6:02 PM

$ICCM

0 · Reply

VlaDracula Jan. 18 at 10:18 PM

$ICCM Compliance deadline (bid price): May 11, 2026 — ICCM must achieve a closing price ≥ $1.00 for 10 consecutive business days by this date to satisfy Nasdaq’s minimum bid price rule. If not we can get another 180days right?

1 · Reply

SuperBusa Jan. 16 at 5:22 PM

$ICCM

0 · Reply

Joe_088 Jan. 16 at 5:07 PM

$VERO 👉👉 $ICCM

1 · Reply

StStephen72 Jan. 16 at 4:59 PM

$ICCM Took small starting position here. 1k at .675 2k at .69 Risk factors are Israel based AND currently Non-compliance on fillings. Pete

0 · Reply

Joe_088 Jan. 16 at 3:05 PM

$ICCM look at $VERO Patience is they key here

0 · Reply

Market Cap	41.98M
Revenue (ttm)	3.29M
Net Income (ttm)	-15.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-465.65%
Debt to Equity Ratio	0.00

Volume	173,300
Avg Vol	335,168
Day's Range	N/A - N/A
Shares Out	68.70M
Stochastic %K	13%
Beta	0.29
Analysts	Strong Sell
Price Target	$3.05